H

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/543,132	04/17/2006	Wilhelmus Maria Van Der Krieken	ARNOLDS-09838	2629	
Christine A Le	7590 11/28/2007 Christine A Lekutis			EXAMINER	
Medlen & Carr	Medlen & Carroll			BELL, KENT L	
Suite 350 101 Howard St	reet		ART UNIT	PÅPER NUMBER	
San Francisco,	San Francisco, CA 94105				
			``		
			MAIL DATE	DELIVERY MODE	
			11/28/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/543,132	VAN DER KRIEKEN ET AL.
Office Action Summary	Examiner	Art Unit
	Kent L. Bell	1661
The MAILING DATE of this communication ap		
• •		
A SHORTENED STATUTORY PERIOD FOR REPI WHICHEVER IS LONGER, FROM THE MAILING I - Extensions of time may be available under the provisions of 37 CFR 1 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period Failure to reply within the set or extended period for reply will, by statu Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	DATE OF THIS COMMUI .136(a). In no event, however, may d will apply and will expire SIX (6) M te. cause the application to become	NICATION. a reply be timely filed ONTHS from the mailing date of this communication. ABANDONED (35 U.S.C. § 133)
Status		
1) Responsive to communication(s) filed on 30 /	<u>August 2007</u> .	
2a) ☐ This action is FINAL . 2b) ☑ Thi	is action is non-final.	
3) ☐ Since this application is in condition for allow		
closed in accordance with the practice under	Ex parte Quayle, 1935 C	.D. 11, 453 O.G. 213.
Disposition of Claims		
4) Claim(s) 1-33 is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) 1-33 is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/	awn from consideration.	
Application Papers		
9) The specification is objected to by the Examin 10) The drawing(s) filed on is/are: a) acceptable and applicant may not request that any objection to the Replacement drawing sheet(s) including the correct and the option of the correct and the option of the second sec	cepted or b) objected to objected to drawing(s) be held in abey ction is required if the drawing.	rance. See 37 CFR 1.85(a). ng(s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority application from the International Bureat * See the attached detailed Office action for a list	nts have been received. Its have been received in ority documents have been received in our documents have been au (PCT Rule 17.2(a)).	Application Noen received in this National Stage
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date August 30, 2007.	Paper N	v Summary (PTO-413) o(s)/Mail Date f Informal Patent Application

Art Unit: 1661

DETAILED ACTION

Election/Restrictions

Applicant's election without traverse of Photine PAQ in the reply filed on August 30, 2007 is acknowledged.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 7, 8, 9, 11, 12, 14, 15, 20, and 27 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 7, 8, 9, 11, 12, 14, 15, 20, and 27 provides for the use of the identification label, but, since the claim does not set forth any steps involved in the method/process, it is unclear what method/process applicant is intending to encompass. A claim is indefinite where it merely recites a use without any active, positive steps delimiting how this use is actually practiced.

Art Unit: 1661

Claims 7, 8, 9, 11, 12, 14, 15, 20, and 27 are rejected under 35 U.S.C. 101 because the claimed recitation of a use, without setting forth any steps involved in the process, results in an improper definition of a process, i.e., results in a claim which is not a proper process claim under 35 U.S.C. 101. See for example *Ex parte Dunki*, 153 USPQ 678 (Bd.App. 1967) and *Clinical Products, Ltd.* v. *Brenner*, 255 F. Supp. 131, 149 USPQ 475 (D.D.C. 1966).

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

Claims 1-18 and 28-32 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Nieuwenhuis et al (6,472,219).

Nieuwenhuis et al. teach a method for providing plants and/or plant parts with an identification label, comprising contacting the plant or plant part with a liquid or powder performed by dipping or immersing in a container containing the tracer molecule, comprising one or more types of tracer molecules, and allowing the plant or plant part to take up the tracer molecules either inside the plant or plant parts or on the surface thereof (Col. 2, lines 21-37).

Application/Control Number: 10/543,132

Art Unit: 1661

Nieuwenhuis et al. further teach wherein the treatment is selected from the group in Claim 10 (Col. 1, lines 28-38).

Page 4

Nieuwenhuis et al. further teach visualization of the label with a source of light (flourometer) (Col. 2, lines 31-33).

Claims 20 and 22 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Nieuwenhuis et al (6,472,219).

Nieuwenhuis et al. teach a plant or plant part carrying an identification label, consisting of one or more types of fluorescent tracer molecules produced by a method comprising, contacting a plant or plant part with a product, comprising one or more types of tracer molecules, and allowing the plant or plant part to take up the tracer molecules either inside the plant or plant parts or on the surface thereof (Col. 2, lines 21-37).

Claims 23-27, and 33 are rejected under 35 U.S.C. 102(e) as being clearly anticipated by Nieuwenhuis et al (6,472,219).

Nieuwenhuis et al. teach a product (flower food) for providing a plant or plant part with an identification label, which product comprises one or more types of tracer molecules wherein the tracer molecules are fluorescent (Col. 2, lines 21-37).

Claim Rejections - 35 USC § 103

Art Unit: 1661

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 19 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nieuwenhuis et al. (6,472,219).

Nieuwenhuis et al. is silent as to wherein the tracer molecule is Photine PAQ.

Examiner respectfully submits that Nieuwenhuis et al. in Column 4 sets forth many if not all of the tracer molecules disclosed in Claims 19 and 21 except for Photine PAQ, however, because Photine PAQ is a well known tracer molecule and there is no significant difference in function between Photine PAQ and any of the other tracer molecules disclosed in Claims 19 and 21, it would have been obvious to one of ordinary skill in the art at the time of the invention to substitute Photine PAQ for any of the tracer

Application/Control Number: 10/543,132 Page 6

Art Unit: 1661

molecules set forth in Claims 19 and 21 to obtain the desired results without undue experimentation.

Future Correspondence

Any inquiry concerning this communication or earlier communications from the Examiner should be directed to Kent L. Bell whose telephone number is (571) 272-0973. The Examiner can normally be reached Monday through Thursday from 6:00 am to 4:30 pm.

If attempts to reach the Examiner by telephone are unsuccessful, the Examiner's supervisor, Anne Marie Grunberg, can be reached at (571) 272-0975.

The fax phone number for the group is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (571) 272-1600.

K. L. Bell

KENT BELL PRIMARY EXAMINER

Kent Bell